Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza
drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a …

Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in
Japan to treat pandemic influenza virus infections. The drug is converted intracellularly into …

Emergence of SARS-CoV-2 causing COVID-19 has resulted in hundreds of thousands of
deaths. In search for key targets of effective therapeutics, robust animal models mimicking …

An emerging infectious disease first identified in central China in 2009, severe fever with
thrombocytopenia syndrome (SFTS) was found to be caused by a novel phlebovirus. Since …

Severe fever with thrombocytopenia syndrome (SFTS) is an acute febrile illness
characterized by fever, leukopenia, thrombocytopenia, and gastrointestinal symptoms such …

Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus
Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality …

First identified in two Missouri farmers exhibiting low white-blood-cell and platelet counts in
2009, Heartland virus (HRTV) is genetically closely related to severe fever with …

Infectious diseases still remain one of the biggest challenges for human health. In order to
gain a better understanding of the pathogenesis of infectious diseases and develop effective …

Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high
mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) …

Severe fever with thrombocytopenia syndrome (SFTS) caused by SFTS virus (SFTSV), a
novel phlebovirus, was reported to be endemic to central and northeastern PR China and …